## A LISTING OF THE CLAIMS

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing. This listing of claims will replace all prior versions and listings of claims in the application:

- 1-27. (Canceled).
- 28. (Previously Presented) An oligonucleotide, comprising: 5'-TGACGTT-3', 5'TGACGTC3' or 5'-AACGTT-3', 8-40 nucleotides in length, wherein each internucleotide linkage has a phosphate backbone modification, wherein the phosphate backbone modification is a phosphorothioate.
- 29. (Previously Presented) An oligonucleotide, comprising: 5'-TGACGTT-3', 5'TGACGTC3' or 5'-AACGTT-3', 8-40 nucleotides in length, and having at least one phosphate backbone modification, wherein the oligonucleotide is linked to a nucleic acid delivery complex.
- 30. (Withdrawn) The oligonucleotide of claim 29, wherein the oligonucleotide is ionically linked to or encapsulated in the nucleic acid delivery complex.
- 31. (Previously Presented) The oligonucleotide of claim 29, wherein the oligonucleotide is covalently linked to the nucleic acid delivery complex.
- 32. (Previously Presented) The oligonucleotide of claim 29, wherein the nucleic acid delivery complex is a cationic lipid.
- 33. (Previously Presented) The oligonucleotide of claim 29, wherein the nucleic acid delivery complex is a sterol.

Application No. 10/789,353 Amendment dated January 12, 2009 After Final Office Action of September 12, 2008

- 34. (Withdrawn) The oligonucleotide of claim 28, wherein the oligonucleotide comprises 5'-TCAACGTT-3'
  - 35. (Canceled).
- 36. (Previously Presented) A composition comprising the oligonucleotide of claim 28 and a pharmaceutically acceptable carrier.